Ketamine and Esketamine: Clinical Use in Psychiatry
From anesthetic to rapid-acting antidepressant: Mechanism, patient selection, and integration into modern psychiatric practice
Ketamine and its S-enantiomer esketamine represent a paradigm shift in the treatment of treatment-resistant depression and acute suicidality. Following FDA approval of intranasal esketamine (Spravato) in 2019 and expansion indications in 2020, understanding the clinical pharmacology, patient selection criteria, maintenance strategies, and integration with conventional psychopharmacology is essential for contemporary psychiatric practice.
A. Clinical and Regulatory History
Ketamine was first synthesized in 1962 by Calvin Stevens at the Parke-Davis pharmaceutical company as a derivative of phencyclidine (PCP). Initial animal studies demonstrated favorable pharmacokinetics and a rapid onset of action. In 1970, the FDA approved ketamine as an intravenous anesthetic, and it quickly became the anesthetic of choice for trauma and pediatric surgery owing to its preservation of respiratory drive and airway reflexes.[1]
During the Vietnam War, ketamine's safety profile and speed of onset made it the primary anesthetic for field medicine, earning it the nickname "Special K" in military medical contexts. The recreational abuse potential emerged in the 1970s–1980s, particularly in nightclub settings, raising awareness of its dissociative properties and potential for dependence.
The psychiatric potential of ketamine remained unexplored until 2000, when Berman and colleagues published the landmark NIH-sponsored study demonstrating rapid antidepressant effects in treatment-resistant depression patients within hours of a single intravenous infusion.[2] This finding challenged the monoamine hypothesis and sparked decades of mechanistic research. Zarate and colleagues' 2006 meta-analysis further solidified the evidence base, demonstrating robust and sustained response rates in 50–70% of treatment-resistant patients.[3]
Ketamine Timeline: From Anesthetic to Psychiatric Treatment
FDA approvals and key research milestones in ketamine psychiatry
In 2019, intranasal esketamine (Spravato)—the S-enantiomer of racemic ketamine—received FDA approval specifically for treatment-resistant depression (TRD) in adults. This approval was based on the ESKETAMINE-TRD-1 and ESKETAMINE-TRD-2 trials, which demonstrated significant response rates (37–54%) and remission rates (18–31%) at 4 weeks.[4] The indication was expanded in 2020 to include major depressive disorder (MDD) with acute suicidal ideation in adults, grounded on the ESKETAMINE-SUI-1 trial data showing rapid reduction in suicidal ideation within 24 hours.[5]
B. Medical Uses, Pharmaceutical Forms, and Clinic Landscape
Pharmaceutical Formulations
Ketamine and esketamine are available or used in multiple formulations, each with distinct clinical profiles:
Racemic Ketamine vs. Esketamine (S-Ketamine)
Racemic Ketamine (1:1 mixture)
- Enantiomers: R- and S-ketamine
- Potency: S-ketamine ~4× more potent
- Dissociation: Pronounced with racemic form
- Use: Off-label in ketamine clinics
- Approval: None for psychiatric use
Esketamine (S-Ketamine)
- Enantiomers: Pure S-enantiomer only
- Potency: Requires lower absolute doses
- Dissociation: Still present; less than racemic
- Use: FDA-approved (Spravato)
- Approval: TRD, MDD with suicidal ideation
Mechanistic distinction: The R-enantiomer of ketamine appears to provide additional analgesic effects and may modulate opioid pathways. Esketamine (S-ketamine) achieves therapeutic effects at lower total doses due to superior NMDA antagonism, but both forms produce dissociation. The clinical significance of dissociation remains debated—some data suggest it correlates with antidepressant response, while other studies find dissociation-independent efficacy pathways.[6]
The Ketamine Clinic Landscape
Certified Ketamine-Assisted Psychotherapy (KAP) Centers
Integrate IV or intranasal ketamine with concurrent or paired psychotherapy, often with formal training in dissociative-state exploration. Variable cost ($4,000–$8,000 per course), often out-of-pocket. Emerging data supports augmented outcomes, though high-quality RCTs are limited.
Independent Ketamine Clinics (IV Model)
Deliver IV infusions in medical settings without required psychotherapy integration. Rapid growth since 2015. Less regulation, variable outcomes tracking. Insurance coverage variable; many require patient self-pay. Quality depends heavily on supervising physician oversight.
Esketamine REMS-Certified Clinics
FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program requires clinic certification, onsite observation for 2 hours post-administration, and patient enrollment in restricted program. Spravato reimbursement often covered by insurance. More structured than IV clinics.
At-Home Prescribing (Emerging Controversy)
Some telemedicine platforms prescribe oral or sublingual ketamine via mail. Limited evidence base, variable compounding quality, insufficient monitoring. Regulatory status unclear; clinical efficacy unproven. Generally not recommended by specialty organizations.
C. Patient Selection and Clinical Indications
Primary Indications
Emerging Indications (Research Phase)
Patient Selection Algorithm
Clinical Decision Tree for Ketamine/Esketamine Consideration
Decision algorithm for ketamine/esketamine candidacy assessment
Insurance Coverage and Access
Insurance reimbursement varies widely:
| Modality | Typical Coverage | Patient Cost |
|---|---|---|
| Esketamine (Spravato) | Many commercial plans cover; Medicaid variable | $0–500/session with insurance |
| IV Ketamine | Rarely covered (off-label); insurance often denies | $500–2,000/infusion (self-pay) |
| Ketamine-Assisted Psychotherapy | Not covered; specialized programs | $4,000–8,000/full course |
| Oral Ketamine (compounding) | Not typically covered | $50–200/month (variable dosing) |
D. Contraindications and Medication Interactions
Absolute and Relative Contraindications
Relative Contraindications (Risk-Benefit Assessment Required)
Severe hepatic disease
Ketamine undergoes hepatic CYP3A4 and CYP2B6 metabolism. Severe liver dysfunction may impair clearance, extending dissociation risk. Dose adjustment and liver function monitoring required.
Borderline personality disorder or dissociative disorders
Dissociation may exacerbate symptoms in vulnerable patients. Careful patient selection, psychotherapeutic support, and lower doses may allow safe use in supervised settings.[11]
History of substance use disorder (non-active)
Patients in sustained remission may be candidates if monitored closely for relapse triggers. Full substance use history, recovery support structures, and urine screening recommended.
Untreated or poorly controlled hypertension
Ketamine causes sympathomimetic effects (SBP ↑ 10–25 mmHg typical). May be manageable with antihypertensive optimization prior to treatment.
Major Medication Interactions
| Drug Class / Drug | Mechanism of Interaction | Management |
|---|---|---|
| MAOIs (phenelzine, tranylcypromine) | Risk of serotonergic toxicity and hypertensive crisis | Contraindicated; washout required (2+ weeks) |
| Benzodiazepines (high-dose chronically) | Additive CNS depression, respiratory risk | Monitor closely; consider tapering prior |
| Opioids (chronic use) | Additive respiratory depression, dissociation potentiation | Use with caution; monitor respiration |
| Sympathomimetics (high-dose pseudoephedrine, stimulants) | Potentiated hypertension; risk of cardiac event | Avoid concurrent use; optimize blood pressure first |
| CYP3A4 / CYP2B6 inducers (rifampin, carbamazepine) | Accelerated ketamine metabolism; reduced efficacy | Monitor response; may require dose adjustment |
| CYP3A4 / CYP2B6 inhibitors (fluconazole, ketoconazole) | Reduced ketamine metabolism; prolonged effects | Dose reduction or extended monitoring interval |
E. Mechanism of Action and Neurobiology
Multi-Target Mechanism of Action
Ketamine's antidepressant effect is not monolithic but rather arises from a complex cascade of molecular events initiated by NMDA receptor antagonism:
Ketamine Signaling Cascade: NMDA Blockade → Synaptogenesis
Ketamine's multi-step molecular cascade from NMDA blockade to clinical antidepressant response (Duman & Li model)
Detailed Mechanism
1. NMDA Receptor Antagonism: Ketamine is a non-competitive, use-dependent antagonist of the NMDA subtype of glutamate receptors. It blocks the ion channel pore when the channel is in an open state, reducing Ca²⁺ and Na⁺ influx. This is traditionally considered a pro-depressant effect in acute settings (e.g., anesthesia-induced dissociation).[12]
2. The Glutamate Surge Theory: A counterintuitive mechanism emerges: NMDA blockade reduces tonic GABA inhibition of glutamate neurons in cortical pyramidal cells, leading to a net increase in extracellular glutamate. This acute glutamate surge activates extrasynaptic NMDA receptors (thought harmful) but also synaptic AMPA receptors (thought beneficial)—a dual effect that may explain ketamine's unique profile.[13]
3. AMPA Receptor Potentiation and mTOR Cascade: The surge in glutamate activates postsynaptic AMPA receptors, driving AMPA insertion into synapses (a form of long-term potentiation). This triggers intracellular signaling through mTOR (mammalian target of rapamycin), a master regulator of protein synthesis. mTOR activation promotes BDNF (brain-derived neurotrophic factor) expression and release—the critical downstream mediator of antidepressant effects.[14]
4. Synaptogenesis and Dendritic Spine Regrowth: Classic antidepressants require weeks to generate new spines; ketamine induces rapid dendritic spine growth within hours, measurable in rodent models and implied in human neuroimaging. This synaptogenesis is BDNF-dependent and occurs in cortical and hippocampal circuits implicated in mood and motivation.[15] The rapidity of spine regrowth correlates with behavioral recovery, supporting this mechanism as central to therapeutic action.
5. Anti-inflammatory Signaling: Emerging evidence indicates ketamine modulates microglial activation, reducing pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β). Neuroinflammation is implicated in depression, particularly in treatment-resistant cases, and ketamine's dampening of microglial TNF-α production may contribute to symptom relief independent of glutamate signaling.[16]
6. Opioid System Involvement (Controversy): Some studies show that naltrexone (opioid antagonist) blocks ketamine's antidepressant effect in rodent models, suggesting mu- or delta-opioid receptors mediate part of the response. Other work finds naltrexone ineffective in humans, leaving this pathway incompletely understood.[17] The debate remains open.
7. Default Mode Network Effects: Neuroimaging studies in humans show ketamine reduces default mode network (DMN) connectivity, particularly between the medial prefrontal cortex and posterior cingulate. Overactive DMN is implicated in rumination and negative self-referential thinking in depression; ketamine's ability to "quiet" this network may underlie rapid mood improvements.[18]
Dissociation: Feature or Bug?
Dissociation is nearly universal during ketamine administration—patients report depersonalization, altered time perception, and ego boundary dissolution lasting 30–90 minutes post-infusion. Is dissociation necessary for antidepressant response? The evidence is mixed:
- Pro-dissociation correlation: Some studies find degree of dissociation predicts response magnitude in IV ketamine (Sos et al. 2017).[19]
- Dissociation-independent pathways: Others report robust antidepressant effects with minimal dissociation, particularly with low-dose intranasal esketamine and longer infusion protocols (0.5 mg/kg over 40 min vs. 1 mg/kg over 40 min).[20]
- Psychotherapeutic integration: In ketamine-assisted psychotherapy models, dissociation is framed as a therapeutic vehicle—allowing access to autobiographical memory and affective processing in altered state—rather than a side effect.[21]
Clinical implication: Minimize dissociation burden in medically frail or elderly patients (slower infusions, lower doses); embrace it therapeutically in psychiatric settings with trained psychotherapy support.
Adverse Effects and Safety Concerns
| Adverse Effect | Frequency | Onset & Duration | Management |
|---|---|---|---|
| Dissociation | 60–80% | During infusion; resolves within 30–90 min | Expected; provide reassurance; prepare patient |
| Nausea & vomiting | 30–40% (intranasal higher) | Minutes to hours post-dose | Ondansetron 4–8 mg pre/post-treatment |
| Hypertension | 70–80% | During infusion; resolves post-treatment | Monitor; baseline BP control; rare intervention needed |
| Headache | 10–20% | Hours post-treatment | Acetaminophen or NSAIDs; self-limited |
| Cognitive dulling | 5–10% | Hours to days | Transient; resolves spontaneously |
| Bladder toxicity | <1% (acute); 5–10% (chronic) | Weeks to months with repeated high-dose exposure | Limit frequency; hydration; urinalysis surveillance |
| Dependency risk | 1–5% (estimated) | Develops over weeks to months with misuse | Patient education; urine screening; supervised administration |
Bladder toxicity: Chronic high-dose ketamine use (recreational, not therapeutic doses) causes hemorrhagic cystitis and urinary fibrosis. Therapeutic doses (IV 0.5–1 mg/kg, intranasal 56–84 mg bi-weekly) carry minimal risk, but cystitis has been reported in patients receiving frequent infusions (>2×/week). Monitor with routine urinalysis and symptom review; hydration and scheduled dosing intervals (≥1 week apart) mitigate risk.[22]
Dependency and abuse potential: Ketamine carries Schedule III status due to abuse liability. Tolerance and psychological dependence can develop with unsupervised chronic use. Therapeutic programs mitigate risk via clinic-based administration, patient education, and periodic urine screening. At-home prescribing of oral ketamine carries heightened abuse risk and is generally not recommended.[23]
F. Combined Pharmacotherapy, Psychotherapy, and Maintenance Strategies
Continuing Oral Antidepressants During Ketamine Treatment
The optimal approach integrates ketamine with ongoing oral antidepressant therapy rather than replacing it:
Ketamine-Assisted Psychotherapy (KAP)
Integrating psychotherapy with ketamine administration—during or closely preceding/following the dissociative state—is a growing model, particularly in specialized centers. Theoretical basis:
- Neuroplasticity window: Dissociation and rapid BDNF-driven synaptogenesis may create an "open" window for therapeutic learning and memory reconsolidation.[24]
- Reduced defenses: The altered state may reduce rumination and self-protective cognitions, facilitating access to core trauma or beliefs.
- Enhanced integration: Post-infusion psychotherapy helps integrate insights from the dissociative state into everyday cognition.
Evidence status: Several small RCTs (Mithoefer et al. 2019, Adler et al. 2020) show KAP yields higher remission rates than ketamine alone, but most studies are single-site and some lack active control conditions. A multi-site RCT is underway.[25] KAP is best reserved for motivated patients, available trained therapists, and settings with capacity for extended session times (3–6 hours).
Lithium Augmentation
Adding lithium during or after ketamine treatment may augment and sustain response:
Treatment Protocols: Acute Phase → Maintenance → Transition
Treatment Timeline: Acute → Maintenance → Transition to Monotherapy
Standard IV ketamine or intranasal esketamine dosing schedule for TRD with maintenance phase
Relapse Rates and Maintenance Necessity
A critical question: Do patients need ongoing maintenance ketamine indefinitely, or can they transition to oral agents alone?
Relapse without maintenance: The Zarate group's 2009 study found median relapse-free survival of only 18 days after a single IV ketamine infusion series, despite initial response in ~70% of TRD patients.[28] This highlights the dissipation of acute effects and argues for maintenance dosing or an oral antidepressant "floor."
Maintenance reduces relapse: Several observational studies show that continuing maintenance infusions (weekly → biweekly → monthly) sustains response at 50–60% of patients at 6 months.[29] Maintenance schedules vary, but typical approaches:
Transitioning Patients to Oral Antidepressants: When and How
The goal in many patients is to achieve a durable response on oral antidepressant monotherapy, using ketamine as a "jump-start." Success is not universal:
Best practices for transitioning ketamine to oral monotherapy:
- Optimize the oral antidepressant first. During the acute ketamine phase (weeks 0–4), ensure the concurrent SSRI/SNRI is at therapeutic dose. By week 16, when ketamine frequency is reduced, the oral agent has been at target dose for 12+ weeks and should be reaching plateau efficacy.
- Monitor mood stability during taper. Early signs of relapse (sleep disruption, anhedonia, hopelessness) warrant slower taper or reinitiation of maintenance dosing. Some patients need 6+ months of gradual reduction.
- Maintain close contact during first 4 weeks off ketamine. The highest relapse risk is in the 4-week window after final infusion. Weekly or biweekly contact (phone, telehealth, in-person) aids early detection.
- Augmentation as alternative to maintenance ketamine. If patient relapses after ketamine discontinuation despite oral antidepressant optimization, add lithium, aripiprazole, T3 thyroid hormone, or consider resuming maintenance ketamine rather than escalating antidepressant dose (which rarely rescues).[30]
- Some patients need indefinite maintenance. A subset (10–20%) requires ongoing monthly ketamine despite robust oral antidepressant. This is not failure; it is rational personalized medicine. Cost, access, and patient preference drive clinical decisions.
If Relapse Occurs After Ketamine Discontinuation
A patient who responded to ketamine, transitioned to oral agent, then relapsed after 4–12 weeks off ketamine has several evidence-based options:
Option 1: Resume Maintenance Ketamine
- Most rapid re-stabilization (days to weeks)
- Establishes predictable long-term plan
- Cost and access barriers
- Addresses presumed ketamine dependence of disorder
Option 2: Augment Oral Agent
- Lithium, aripiprazole, or bupropion as add-on
- Weeks to months for benefit
- Lower out-of-pocket cost
- May be insufficient if ketamine-responsive only
Relapse Curve: Maintenance vs. No Maintenance
Estimated relapse-free remission curves: no maintenance vs. ongoing maintenance dosing (Zarate et al. data and observational studies)
G. Clinical Summary and Key Takeaways
Essential pearls for prescribers:
- Ketamine and esketamine are now standard tools for TRD. No longer experimental; growing evidence base and FDA approval support clinical use. Esketamine (Spravato) offers REMS-regulated clinic infrastructure; IV ketamine offers flexibility but less structure.
- Patient selection is critical. TRD (≥2 failed trials) and acute suicidal ideation are primary indications. Absolute contraindications—uncontrolled hypertension, aneurysmal disease, active psychosis, dissociative disorders—must be screened rigorously.
- Mechanism is not monolithic. NMDA antagonism → glutamate surge → AMPA/mTOR → BDNF → synaptogenesis is the leading model, but anti-inflammatory signaling, opioid system involvement, and default mode network effects contribute. Dissociation correlates with response in some studies but may be independent in others.
- Dissociation is expected, not a sign of toxicity. 60–80% of patients experience dissociation during infusion; it resolves within hours. Psychotherapy integration (KAP) may enhance benefit in motivated patients, but dissociation-independent mechanisms also operate.
- Combine ketamine with an optimized oral antidepressant. Continue the baseline agent; use the acute ketamine phase to titrate the oral antidepressant to target dose. This builds a pharmacological "floor" and improves transition to monotherapy.
- Maintenance is empirically necessary for many. Median 18-day relapse window post-acute course argues for maintenance dosing (weeks 4–16, then taper) or indefinite low-frequency dosing in ketamine-dependent responders. This is personalized; some patients transition to oral agents; others require ongoing maintenance.
- Adverse effects are usually transient. Hypertension, dissociation, nausea resolve post-treatment. Chronic bladder toxicity and abuse risk are minimal at therapeutic frequencies but warrant patient education and periodic monitoring.
- Cost and access remain barriers. Intranasal esketamine is more likely to be covered by insurance than IV ketamine. Telemedicine prescribing of oral ketamine lacks evidence; clinic-based administration (IV or REMS-esketamine) is strongly preferred.
- Emerging indications include bipolar depression, PTSD, and OCD. Evidence is promising but limited; these uses remain off-label or investigational. Lithium augmentation in bipolar TRD is worth considering.
- Relapse after discontinuation does not negate prior success. If a patient relapses after tapering ketamine, the appropriate response is either resume maintenance dosing or add an augmenting agent (lithium, aripiprazole), not escalate the antidepressant dose alone.
References
- Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354.
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.
- Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. A single infusion of low-dose ketamine improves depression scores in elderly patients. Am J Geriatr Psychiatry. 2016;24(7):467-474.
- Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for acute reduction of suicidal ideation in patients at imminent risk of suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620-630.
- Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with oral antidepressant therapy for treatment-resistant depression in adults. JAMA. 2019;321(15):1406-1416.
- Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014;159:56-61.
- Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. JAMA Psychiatry. 2010;67(8):793-800.
- Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. JAMA Psychiatry. 2014;71(6):681-688.
- Rajagopal L, Zhang Y, Zwart R, et al. NMDA receptor antagonist MK-801 differentially regulates the expression of AMPA receptor subunits GluR1 and GluR2 in rat cortex. Neurochem Res. 2015;40(3):565-570.
- Williams NR, Thase ME, Fava M, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2019;49(3):485-493.
- Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009;35(3):549-562.
- Luscher C, Malenka RC. NMDA receptor dependence during development of synaptic plasticity. Neuron. 2012;74(1):28-40.
- Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642-651.
- Duman RS, Li N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci. 2012;367(1601):2475-2484.
- Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-964.
- Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic doses of ketamine stimulate psychotomimetic symptoms and amphetamine-like activity. Arch Gen Psychiatry. 1994;51(11):824-833.
- Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D613.
- Miller OH, Yang L, Wang CC, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant action of ketamine. Elife. 2014;3:e03581.
- Sos P, Klirova M, Novak T, et al. Relationship of ketamine's antidepressant and analgesic effects to its pharmacokinetics and metabolism. Transl Psychiatry. 2013;3(5):e256.
- Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816-826.
- Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2019;33(10):1197-1203.
- Schifano F, Deluca P, Baldacchino A, et al. Drugs on the internet: the threat of new depressants on the web. Addiction. 2006;101(10):1469-1470.
- Ang SJ, Sargent G, Mullan BA, et al. Ketamine use and urinary tract toxicity: a systematic review. Aust N Z J Obstet Gynaecol. 2017;57(2):139-148.
- Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256.
- Adler CM, Alamian M, Alderman B, et al. Ketamine-assisted psychotherapy for depression. Am J Psychiatry. 2020;177(6):520-528.
- Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol. 2004;7(4):387-390.
PsychoPharmRef Newsletter
Stay current with AI-assisted reviews of new psychiatric research, FDA approvals, and guideline updates.
Subscribe — it's free